Robert Busch, MD: Topline Results of EMPEROR-REDUCED
In this episode we will be discussing reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocrinologist Dr. Robert Busch.
Announced on July 30, by Berringer Ingelheim and Lilly,topline results indicate use of empagliflozin was associated with a decrease in the composite endpoint of CV deat...
17m
•
Jul 31, 2020